Protalix Biotherapeutics Inc. buy stratec
Start price
03.02.18
/
50%
€5.13
Target price
04.11.21
€4.00
Performance (%)
-81.68%
End price
05.11.21
€0.94
Summary
This prediction ended on 05.11.21 with a price of €0.94. Massive losses of -81.68% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc. | 4.167% | 4.167% | -13.018% | 33.869% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
Comments by stratec for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix is a Buy for investors who are patient and brave...
Protalix has the first FDA-approved plant cell expressed protein, Elelyso for Gaucher disease, and has three other drug candidates in its pipeline.
Protalix recently inked a deal with Chiesi for the commercialization of PRX-102 worldwide (except in the USA). Phase 3 interim data for its Fabry disease franchise will be reported in 2018. PRX-102 has less antibody formation (and antibodies only stay in the body briefly).
The orphan disease market is lucrative with PRX-102 to potentially become the new standard of care.
stratec stimmt am 03.02.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 5.22€ zu.
Kursziel geändert auf 2,2
Kursziel geändert auf 3,0
Kursziel geändert auf 4,0
In the thread Trading Protalix Biotherapeutics Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten